| US 7,547,710 B2 | ||
| Fused heterocyclic compounds as peptidase inhibitors | ||
| Satoru Oi, Nara (Japan); Hironobu Maezaki, Toyonaka (Japan); and Koji Ikedou, Himeji (Japan) | ||
| Assigned to Takeda Pharmaceutical Company Limited, Osaka (Japan) | ||
| Appl. No. 10/523,531 PCT Filed Aug. 07, 2003, PCT No. PCT/JP03/10054 § 371(c)(1), (2), (4) Date Feb. 07, 2005, PCT Pub. No. WO2004/014860, PCT Pub. Date Feb. 19, 2004. |
||
| Claims priority of application No. 2002-231950 (JP), filed on Aug. 08, 2002; and application No. 2003-51575 (JP), filed on Feb. 27, 2003. | ||
| Prior Publication US 2006/0135530 A1, Jun. 22, 2006 | ||
| Int. Cl. A61K 31/47 (2006.01); C07D 215/12 (2006.01) | ||
| U.S. Cl. 514—311 [546/173] | 11 Claims |
1. A compound represented by the formula
 ring A is an optionally substituted 5- to 10-membered aromatic ring;
one of R1 and R2 is an optionally substituted phenyl group and the other is an optionally substituted C1-10 alkyl group;
both X and Y are bonds: and
L is a C1-10 alkylene group,
or a salt thereof.
|